Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2840
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study ; volume:15 ; number:1 ; day:26 ; month:7 ; year:2016 ; pages:1-10 ; date:12.2016
Cardiovascular diabetology ; 15, Heft 1 (26.7.2016), 1-10, 12.2016
- Creator
-
Kumarathurai, Preman
- Contributor
-
Anholm, Christian
Nielsen, Olav W.
Kristiansen, Ole P.
MøLvig, Jens
MADSBAD, STEN
Haugaard, Steen B.
Sajadieh, Ahmad
SpringerLink (Online service)
- DOI
-
10.1186/s12933-016-0425-2
- URN
-
urn:nbn:de:1111-2016072742009
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kumarathurai, Preman
- Anholm, Christian
- Nielsen, Olav W.
- Kristiansen, Ole P.
- MøLvig, Jens
- MADSBAD, STEN
- Haugaard, Steen B.
- Sajadieh, Ahmad
- SpringerLink (Online service)
Other Objects (12)
Glucagon-like peptide-1 receptor agonist, liraglutide, attenuated retinal thickening in spontaneously diabetic Torii fatty rats
Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition
Effects of the long-acting glucagon-like peptide-1 receptor agonist liraglutide in adolescent pigs with impaired glucose-dependent insulinotropic polypeptide receptor function
Effects of the long-acting glucagon-like peptide-1 receptor agonist liraglutide in adolescent pigs with impaired glucose-dependent insulinotropic polypeptide receptor function
Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
Glucagon-like peptide 1 (GLP-1)
„Glucagon-like peptide‑1“(GLP‑1)-Rezeptor-Agonisten – die neuen Wunderwaffen in der Adipositastherapie?
Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity
Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes
Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017–2022
Glucagon-like peptide-1 7-36 amid
Comprehensive characterization of cardiovascular protection by the GLP-1 (Glucagon-like peptide-1) analog liraglutide in experimental arterial hypertension
Glucagon-like peptide-1 receptor agonist, liraglutide, attenuated retinal thickening in spontaneously diabetic Torii fatty rats
Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition
Effects of the long-acting glucagon-like peptide-1 receptor agonist liraglutide in adolescent pigs with impaired glucose-dependent insulinotropic polypeptide receptor function
Effects of the long-acting glucagon-like peptide-1 receptor agonist liraglutide in adolescent pigs with impaired glucose-dependent insulinotropic polypeptide receptor function
Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
Glucagon-like peptide 1 (GLP-1)
„Glucagon-like peptide‑1“(GLP‑1)-Rezeptor-Agonisten – die neuen Wunderwaffen in der Adipositastherapie?
Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity
Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes
Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017–2022
Glucagon-like peptide-1 7-36 amid
Comprehensive characterization of cardiovascular protection by the GLP-1 (Glucagon-like peptide-1) analog liraglutide in experimental arterial hypertension
Glucagon-like peptide-1 receptor agonist, liraglutide, attenuated retinal thickening in spontaneously diabetic Torii fatty rats
Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition
Effects of the long-acting glucagon-like peptide-1 receptor agonist liraglutide in adolescent pigs with impaired glucose-dependent insulinotropic polypeptide receptor function
Effects of the long-acting glucagon-like peptide-1 receptor agonist liraglutide in adolescent pigs with impaired glucose-dependent insulinotropic polypeptide receptor function
Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
Glucagon-like peptide 1 (GLP-1)
„Glucagon-like peptide‑1“(GLP‑1)-Rezeptor-Agonisten – die neuen Wunderwaffen in der Adipositastherapie?
Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity
Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes
Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017–2022
Glucagon-like peptide-1 7-36 amid